For instance, a randomized clinical trial in hormone receptor-positive, HER2-negative metastatic breast cancer patients did not observe significant differences in median PFS or ORR when Eribulin was combined with pembrolizumab compared to Eribulin monotherapy (50). This evidence concerns the gene ERBB2 and breast cancer.